0001246360-15-000989.txt : 20150219
0001246360-15-000989.hdr.sgml : 20150219
20150219162109
ACCESSION NUMBER: 0001246360-15-000989
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20150217
FILED AS OF DATE: 20150219
DATE AS OF CHANGE: 20150219
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: SYNAGEVA BIOPHARMA CORP
CENTRAL INDEX KEY: 0000911326
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 561808663
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 33 HAYDEN AVE.
CITY: LEXINGTON
STATE: MA
ZIP: 02421
BUSINESS PHONE: (781) 357-9900
MAIL ADDRESS:
STREET 1: 33 HAYDEN AVE.
CITY: LEXINGTON
STATE: MA
ZIP: 02421
FORMER COMPANY:
FORMER CONFORMED NAME: TRIMERIS INC
DATE OF NAME CHANGE: 19970516
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: BOESS CARSTEN
CENTRAL INDEX KEY: 0001277495
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-23155
FILM NUMBER: 15632018
MAIL ADDRESS:
STREET 1: C/O ALEXION PHARMACEUTICALS
STREET 2: 352 KNOTTER DR
CITY: CHESHIRE
STATE: CT
ZIP: 06410
4
1
form.xml
PRIMARY DOCUMENT
X0306
4
2015-02-17
false
0000911326
SYNAGEVA BIOPHARMA CORP
GEVA
0001277495
BOESS CARSTEN
33 HAYDEN AVE
LEXINGTON
MA
02421
false
true
false
false
SVP, Chief Financial Officer
Common Stock
2015-02-17
4
M
false
13235
1.7
A
13235
D
Common Stock
2015-02-17
4
M
false
29062
40.74
A
42297
D
Common Stock
2015-02-17
4
S
false
8989
98.85
D
33308
D
Common Stock
2015-02-17
4
S
false
14750
99.97
D
18558
D
Common Stock
2015-02-17
4
S
false
16716
100.74
D
1842
D
Common Stock
2015-02-17
4
S
false
1842
101.69
D
0
D
Stock Option (Right to Buy)
1.7
2015-02-17
4
M
false
13235
0
D
2021-05-25
Common Stock
13235
9929
D
Stock Option (Right to Buy)
40.74
2015-02-17
4
M
false
29062
0
D
2022-06-27
Common Stock
29062
15938
D
The stock option exercise and sale of shares of the Company's common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan adopted by the reporting person on September 24, 2014.
The Stock Option granted the reporting person an option to purchase 158,840 shares of the Company's common stock (the "Shares"). 25% of the Shares vested and became exercisable on 05/16/2012, and 1/36 of the remainder of the Shares vest and become exercisable monthly thereafter.
The Stock Option granted the reporting person an option to purchase 45,000 shares of the Company's common stock (the "Shares"). 25% of the Shares vested and became exercisable on 06/27/ 2013 and 1/36 of the remainder of the Shares vest and become exercisable monthly thereafter.
This transaction was executed in multiple trades through a broker-dealer at prices ranging from $98.34 to $99.32. The price reported in this row reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
This transaction was executed in multiple trades through a broker-dealer at prices ranging from $99.36 to $100.35. The price reported in this row reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
This transaction was executed in multiple trades through a broker-dealer at prices ranging from $100.45 to $101.37. The price reported in this row reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
This transaction was executed in multiple trades through a broker-dealer at prices ranging from $101.56 to $101.97. The price reported in this row reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
/s/ Carsten Boess
2015-02-19